| |
 |
 |
CBI's extensive knowledge of the biopharmaceutical industry, investment expertise, strategic relationships including extensive network of academic and industry contacts all come together to successfully create a flourishing portfolio of biotechnology companies. These companies generate strong returns to their shareholders and are rapidly becoming leaders in their respective fields: from computational genomics and cancer detection and therapeutics through medical preparations for chronic wounds to selective drug targeting and delivery for the central nervous system.
Our unique strategy together with our strong resources assists our portfolio companies through the challenges of product and business development. We help recruit management executives and advisors, identify complementary technology and products, negotiate agreements, develop business strategies, and ensure successful follow-on financings.
| Company |
Holdings |
Field |
Stage |
| Polyheal |
40% |
Wound Healing |
Approved for marketing |
| MediWound |
55% |
Severe Burns |
Phase III |
| D-Pharm |
47% |
Ischemic Stroke |
Phase III |
| Andromeda |
90% |
Type 1 Diabetes |
Phase III |
| CureTech |
39% |
Cancer |
Phase II |
| Gamida Cell |
20% |
Cancer |
Phase III |
| BioCancell |
19% |
Cancer |
Phase II |
| Apposense |
4% |
Cancer, Stroke |
Phase II |
| Avraham |
15% |
Alzheimer |
Phase II |
| Biokine |
33% |
Cancer |
Phase I |
| BrainTact |
24% |
Cancer, ALS |
PC |
| Thrombotech |
41% |
Stroke |
PC |
| Protab |
16% |
RA |
PC |
| Campus Bio |
100% |
Drug
Development |
|
| CLS |
100% |
GMP Facility |
|
|
|
|
